https://pharmadevicenews.com/world-adc-2026-highlights-invenras-approach-to-her2-and-her3-targeting/ PharmaDeviceNews en 2026-10-12T17:28:36+00:00 World ADC 2026 highlights Invenra’s approach to HER2 and HER3 targeting 52 Views of Cancer, B-Body, Bonnie Hammer, HER2, HER3, HYPER-Internalization, Invenra Inc., Roland Green, T-Body, World ADC San Diego, Xcellon Biologics https://pharmadevicenews.com/wp-content/uploads/2026/08/Bispecific-antibodies-could-offer-an-off-the-shelf-route-to-immune-system-reset-e1787484479745.webp https://pharmadevicenews.com/fujifilms-new-pathology-ai-can-classify-tissue-changes-but-is-it-ready-for-cancer-diagnosis/ PharmaDeviceNews en 2026-10-12T17:15:58+00:00 Fujifilm’s new pathology AI can classify tissue changes, but is it ready for cancer diagnosis? Fujifilm, FUJIFILM Healthcare Americas Corporation, FUJIFILM Holdings Corporation, Ibex Medical Analytics, Inspirata, Mark Lloyd, Pathology Visions, San Diego, Synapse AI Orchestrator, Synapse Pathology, Synapse Pathology AI Foundry, TissueDirect, TissueSync https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Cancer-generic.webp https://pharmadevicenews.com/can-insulets-new-diabetes-data-platform-improve-time-in-range-and-patient-engagement/ PharmaDeviceNews en 2026-10-12T15:56:55+00:00 Can Insulet’s new diabetes data platform improve time in range and patient engagement? Abbott Diabetes Care, American Diabetes Association, DexCom, Glooko, Insulet Corporation, Omnipod 5, Omnipod Discover, Pablo Mora, PodderCentral, Trang Ly https://pharmadevicenews.com/wp-content/uploads/2026/07/Omnipod-5-Spain-rollout-could-reshape-access-to-tubeless-automated-insulin-delivery-e1783408752829.webp https://pharmadevicenews.com/what-the-aloft-ipf-results-mean-for-bristol-myers-squibb-and-pulmonary-fibrosis-treatment/ PharmaDeviceNews en 2026-10-12T15:53:49+00:00 What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment Admilparant, ALOFT-IPF, ALOFT-PPF, BMS-986278, Boehringer Ingelheim, Bristol Myers Squibb, Esbriet, Jascayd, nerandomilast, Ofev, Roche, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/PureTech-founded-Celea-begins-Phase-3-test-of-deupirfenidone-in-idiopathic-pulmonary-fibrosis-e1783930649592.webp https://pharmadevicenews.com/brent-saunders-exits-bausch-lomb-just-as-earnings-improve-what-changes-under-thomas-appio/ PharmaDeviceNews en 2026-10-12T15:50:13+00:00 Brent Saunders exits Bausch + Lomb just as earnings improve. What changes under Thomas Appio? Bausch + Lomb, Bausch Health, Biotrue, Brent Saunders, MIEBO, Thomas J. Appio, ULTRA, XIIDRA https://pharmadevicenews.com/wp-content/uploads/2026/07/Aravind-Eye-Care-System-and-Alcon-open-global-retina-surgery-training-centre-in-Coimbatore-e1784901204737.webp https://pharmadevicenews.com/bristol-myers-squibbs-4-1bn-rayzebio-acquisition-delivers-clinical-milestone/ PharmaDeviceNews en 2026-10-12T15:46:13+00:00 Bristol Myers Squibb’s $4.1bn RayzeBio acquisition delivers clinical milestone Actinium-225, ACTION-1, Amreen Husain, Bristol Myers Squibb, DOTATATE, Indianapolis, Lutathera, Novartis, RayzeBio, RYZ101, Simron Singh, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/Tract-Bio-AACR-data-puts-TP101-on-a-pre-IND-path-for-epithelial-solid-tumors-e1784691281153.webp https://pharmadevicenews.com/can-teleflexs-freesolve-scaffold-challenge-permanent-drug-eluting-stents/ PharmaDeviceNews en 2026-10-12T15:42:11+00:00 Can Teleflex’s Freesolve scaffold challenge permanent drug-eluting stents? Abbott Laboratories, BIOMAG-I, BIOMAG-II, BIOMAG-III, BIOMAG-LL, BIOTRONIK, European Union, Flavio Ribichini, Freesolve, Georg Nollert, Ron Waksman, Teleflex Incorporated, United States Food and Drug Administration, Xience https://pharmadevicenews.com/wp-content/uploads/2026/07/Elucid-AI-PREDICT-study-begins-testing-lesion-level-heart-attack-risk-with-CCTA-e1783862389127.webp https://pharmadevicenews.com/johnson-johnson-reports-long-term-icotyde-efficacy-and-safety-in-plaque-psoriasis/ PharmaDeviceNews en 2026-10-12T15:04:48+00:00 Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis Fall Clinical Dermatology, ICONIC-ADVANCE, ICONIC-LEAD, ICONIC-TOTAL, icotrokinra, ICOTYDE, Johnson & Johnson, Protagonist Therapeutics, Sotyktu, TREMFYA, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-15-2026-09_17_45-AM-e1789444118165.webp https://pharmadevicenews.com/eli-lillys-together-pso-trial-links-obesity-treatment-with-psoriasis-improvement/ PharmaDeviceNews en 2026-10-12T15:00:56+00:00 Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement Eli Lilly and Company, Fall Clinical Dermatology Conference, ixekizumab, James G. Krueger, Las Vegas, Mark Genovese, Taltz, The Rockefeller University, tirzepatide, TOGETHER-PsA, TOGETHER-PsO, Zepbound https://pharmadevicenews.com/wp-content/uploads/2026/04/Foundayo-gives-Eli-Lilly-and-Company-a-new-obesity-edge-but-execution-risk-still-matters-e1775232125399.webp https://pharmadevicenews.com/perceive-biotherapeutics-completes-voy-101-phase-2a-journey-enrollment-in-geographic-atrophy/ PharmaDeviceNews en 2026-10-12T14:56:40+00:00 Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy Apellis Pharmaceuticals, Astellas Pharma, Aura Biosciences, Complement Factor H, Iveric Bio, Izervay, JOURNEY, K. Angela Macfarlane, Ocugen, Perceive Biotherapeutics, Syfovre, Tony Gibney, United States Food and Drug Administration, VOY-101 https://pharmadevicenews.com/wp-content/uploads/2026/09/Retinal-imaging-e1788296418499.webp https://pharmadevicenews.com/why-thermedicals-durablate-catheter-could-address-difficult-to-reach-heart-arrhythmias/ PharmaDeviceNews en 2026-10-12T14:52:24+00:00 Why Thermedical’s Durablate catheter could address difficult-to-reach heart arrhythmias Dalhousie University, David J. Callans, Durablate, John Sapp Jr., Michael Curley, Montreal Heart Institute, SERF Ablation System, Thermedical, U.S. Food and Drug Administration, University of Colorado School of Medicine, Wendy S. Tzou https://pharmadevicenews.com/wp-content/uploads/2026/08/Medtronics-Affera-Mapping-and-Ablation-System-with-the-Sphere-9-catheter-e1786272248201.webp https://pharmadevicenews.com/kyowa-kirin-poteligeo-mint-study-shows-62-4-response-in-cutaneous-t-cell-lymphoma/ PharmaDeviceNews en 2026-10-12T14:47:34+00:00 Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma Chalid Assaf, Charité Universitätsmedizin Berlin, European Organisation for Research and Treatment of Cancer, Germany, Helios Klinikum Krefeld, Kyowa Kirin, Kyowa Kirin International, MAVORIC, Mint, Mogamulizumab, mycosis fungoides, Poteligeo, Sézary syndrome https://pharmadevicenews.com/wp-content/uploads/2026/08/T-cell-lymphoma-samples-analysis-e1787865349190.webp https://pharmadevicenews.com/artemis-care-compass-and-aiva-bring-ai-powered-workflow-tools-to-fertility-clinics/ PharmaDeviceNews en 2026-10-12T06:49:58+00:00 Artemis Care Compass and AiVA bring AI-powered workflow tools to fertility clinics AiVA, AiVA Talk, Artemis, Artemis Care Compass, Artemis Insights, Artemis Messenger, Artemis Pulse Check, Boston IVF, IVI RMA Global, IVI RMA North America, James DiLella, Lynn Mason, Reproductive Medicine Associates, Thomas Molinaro, TRIO Fertility https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/how-lux-infusion-plans-to-improve-qfitlia-access-and-treatment-coordination/ PharmaDeviceNews en 2026-10-12T06:46:16+00:00 How Lux Infusion plans to improve Qfitlia access and treatment coordination Fitusiran, Florida, Frazier Healthcare Partners, Genzyme Corporation, Lux Infusion, Plantation, Qfitlia, Sanofi, Siemens Healthineers, Ted Kramm, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/subcutaneous-injection-for-hemophilia-management.webp https://pharmadevicenews.com/biomarin-seeks-fda-approval-for-voxzogo-in-hypochondroplasia-after-phase-3-success/ PharmaDeviceNews en 2026-10-12T06:36:50+00:00 BioMarin seeks FDA approval for Voxzogo in hypochondroplasia after Phase 3 success American Society for Bone and Mineral Research, ASPEN, BioMarin Pharmaceutical Inc., BMN 333, CANOPY-HCH-3, European Medicines Agency, United States Food and Drug Administration, vosoritide, VOXZOGO https://pharmadevicenews.com/wp-content/uploads/2026/05/BioMarins-VOXZOGO-data-deepen-the-case-for-earlier-intervention-in-achondroplasia-e1777820741263.webp https://pharmadevicenews.com/can-surgentecs-vantage-system-reduce-surgical-instrumentation-and-sterilisation-requirements/ PharmaDeviceNews en 2026-10-12T06:29:05+00:00 Can SurGenTec’s Vantage system reduce surgical instrumentation and sterilisation requirements? Allevion Medical, ELID System, ION-L, LESspine Innovations, SurGenTec, U.S. Food and Drug Administration, Vantage https://pharmadevicenews.com/wp-content/uploads/2026/10/SurGenTec-expands-minimally-invasive-spine-surgery-portfolio-with-disposable-Vantage-system-scaled-e1791786468794.webp https://pharmadevicenews.com/aviadobio-avb-101-shows-90-progranulin-increase-in-phase-1-2-aspire-ftd-trial/ PharmaDeviceNews en 2026-10-12T06:24:21+00:00 AviadoBio AVB-101 shows 90% progranulin increase in Phase 1/2 ASPIRE-FTD trial Alector, Alzheimer’s Drug Discovery Foundation, ASPIRE-FTD, Astellas Pharma, AVB-101, AviadoBio, David Cooper, GRN, INFRONT-3, James Rowe, Latozinemab, Rik Vandenberghe, University Hospitals Leuven, University of Cambridge https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/anx-robotica-highlights-133-patient-artic-study-supporting-proscan-ai-performance/ PharmaDeviceNews en 2026-10-12T05:21:18+00:00 AnX Robotica highlights 133-patient ARTIC study supporting ProScan AI performance Ankon Technologies, AnX Robotica, ARTIC, CapsoCam Plus, CapsoCloud, CapsoView, CapsoVision, NaviCam ProScan, The Lancet Digital Health, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/07/AnX-Robotica-launches-NaviCONNECT-for-cloud-based-capsule-endoscopy-workflow-management-e1785132503811.webp https://pharmadevicenews.com/celltrion-presents-liberty-cd-and-liberty-uc-post-hoc-findings-at-acg-2026/ PharmaDeviceNews en 2026-10-12T05:17:15+00:00 Celltrion presents LIBERTY-CD and LIBERTY-UC post hoc findings at ACG 2026 American College of Gastroenterology, Celltrion, Celltrion USA, Icahn School of Medicine at Mount Sinai, Infliximab-dyyb, LIBERTY-CD, LIBERTY-UC, Marla Dubinsky, Nashville, Remsima SC, U.S. Food and Drug Administration, Zymfentra https://pharmadevicenews.com/wp-content/uploads/2026/05/02ea940e-a8c9-4dba-abdd-45fa19fe54f2-e1778952401377.webp https://pharmadevicenews.com/sebela-pharmaceuticals-reports-positive-acg-2026-data-for-tegoprazan-in-reflux-disease/ PharmaDeviceNews en 2026-10-12T05:13:43+00:00 Sebela Pharmaceuticals reports positive ACG 2026 data for tegoprazan in reflux disease American College of Gastroenterology, Braintree Laboratories, HK inno.N, K-CAB, Lansoprazole, Sebela Pharmaceuticals, Tegoprazan, TRIUMpH-EE, TRIUMpH-NERD, United States Food and Drug Administration, Vonoprazan, Voquezna https://pharmadevicenews.com/wp-content/uploads/2026/08/FDA-clears-the-biggest-hurdle-for-Implantica-as-RefluxStop-enters-the-US-anti-reflux-surgery-market-e1787317857866.webp https://pharmadevicenews.com/skyrizi-reaches-73-1-remission-in-a-crohns-subgroup-can-abbvie-secure-a-new-fda-dosing-option/ PharmaDeviceNews en 2026-10-12T05:10:10+00:00 Skyrizi reaches 73.1% remission in a Crohn’s subgroup. Can AbbVie secure a new FDA dosing option? AbbVie, AFFIRM, American College of Gastroenterology, COMMAND, FORTIFY, guselkumab, Rinvoq, risankizumab, SEQUENCE, SKYRIZI, U.S. Food and Drug Administration, Upadacitinib https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/mirums-expand-study-tests-maralixibat-for-treatment-resistant-cholestatic-pruritus/ PharmaDeviceNews en 2026-10-12T05:07:07+00:00 Mirum’s EXPAND study tests maralixibat for treatment-resistant cholestatic pruritus Alagille Syndrome, Biliary Atresia, Chris Peetz, EMBARK, European Medicines Agency, EXPAND, LIVMARLI, maralixibat, MARCH-PFIC, Mirum Pharmaceuticals, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/mirum_livmarli_expand_phase3_infographic-e1791781571237.webp https://pharmadevicenews.com/one-abcl635-injection-cut-hot-flashes-by-83-can-abcellera-prove-the-benefit-lasts/ PharmaDeviceNews en 2026-10-12T04:15:08+00:00 One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts? AbCellera Biologics Inc., ABCL635, Astellas Pharma, Bayer, International Menopause Society, Lynkuet, San Diego, The Menopause Society, Veozah https://pharmadevicenews.com/wp-content/uploads/2026/10/AbCelleras-ABCL635-Data-Reveal-e1791778450604.webp https://pharmadevicenews.com/can-spruce-biosciences-prove-its-sanfilippo-treatment-slows-brain-decline-new-data-could-strengthen-its-fda-case/ PharmaDeviceNews en 2026-10-12T04:08:41+00:00 Can Spruce Biosciences prove its Sanfilippo treatment slows brain decline? New data could strengthen its FDA case Child Neurology Society, Cure Sanfilippo Foundation, Denali Therapeutics, Gazi University, Ilyas Okur, Montreal, MPS IIIB, National MPS Society, Sanfilippo Syndrome Type B, Spruce Biosciences, TA-ERT, Tralesinidase Alfa, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Spruce-Biosciences-Biotech-Progress-Timeline-e1791778069222.webp https://pharmadevicenews.com/why-leo-pharma-is-investing-in-real-world-evidence-for-difficult-dermatological-diseases/ PharmaDeviceNews en 2026-10-12T04:03:07+00:00 Why LEO Pharma is investing in real-world evidence for difficult dermatological diseases Adbry, ADHAND, Adtralza, Anzupgo, DELTA TEEN, EFFISAYIL, European Medicines Agency, Las Vegas, LEO Pharma, Spevigo, TRACE, TRAPEDS 1, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Amyloidosis-PET-Tracer_-94-Sensitivity-1-e1791777734694.webp https://pharmadevicenews.com/bayers-experimental-pet-scan-detected-94-of-cardiac-amyloidosis-cases-can-it-identify-the-disease-earlier/ PharmaDeviceNews en 2026-10-12T03:56:47+00:00 Bayer’s experimental PET scan detected 94% of cardiac amyloidosis cases. Can it identify the disease earlier? Bayer AG, Brigham and Women's Hospital, CONFIRMATION-HF, FINALITY-HF, FINEARTS-HF, Finerenone, Heart Failure Society of America, Iodine 124 Evuzamitide, Kerendia, REDEFINE-HF, REVEAL, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Amyloidosis-PET-Tracer_-94-Sensitivity-e1791777330136.webp https://pharmadevicenews.com/ginkgo-bioworks-joins-1-5-billion-nsf-x-labs-push-with-autonomous-laboratory-access/ PharmaDeviceNews en 2026-10-12T03:50:07+00:00 Ginkgo Bioworks joins $1.5bn NSF X-Labs push with autonomous laboratory access California Institute of Technology, Eli Lilly and Company, Ginkgo Bioworks, Ginkgo Cloud Lab, Ginkgo Datapoints, Jason Kelly, Massachusetts Institute of Technology, Michael Kratsios, National Science Foundation, Nebula, Northwestern University, NSF X-Labs, Pacific Northwest National Laboratory, University of Maryland https://pharmadevicenews.com/wp-content/uploads/2026/10/Ginkgo-Bioworks-X-Labs-Funding-Infographic-e1791776953291.webp https://pharmadevicenews.com/how-guardant360-cdx-detects-esr1-mutations-before-breast-cancer-progresses-on-imaging/ PharmaDeviceNews en 2026-10-11T17:45:51+00:00 How Guardant360 CDx detects ESR1 mutations before breast cancer progresses on imaging AstraZeneca, camizestrant, Etcamah, European Commission, European Medicines Agency, Guardant Health, Guardant360 CDx, SERENA-6, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/10/Guardant360-CE-Marking-for-ESR1-Testing-e1791740705862.webp https://pharmadevicenews.com/betterup-canada-launches-ontario-frontline-study-to-test-mental-health-coaching/ PharmaDeviceNews en 2026-10-11T17:38:13+00:00 BetterUp Canada launches Ontario Frontline Study to test mental health coaching BetterUp, BetterUp Canada, Kate Niederhoffer, Lesley Lutes, Martin Seligman, Ontario, Ontario Frontline Study, University of British Columbia, University of Pennsylvania, Workplace Safety and Insurance Board, World Health Organization https://pharmadevicenews.com/wp-content/uploads/2026/10/Virtual-Coaching-for-Ontario-First-Responders-e1791740228949.webp https://pharmadevicenews.com/can-me-therapeutics-cd19-cd22-car-designs-address-resistance-in-b-cell-cancers/ PharmaDeviceNews en 2026-10-11T17:31:47+00:00 Can ME Therapeutics’ CD19 CD22 CAR designs address resistance in B-cell cancers? Canada, Canadian Securities Exchange, CD19, CD22, CLIC-2201, ME Therapeutics Holdings Inc., Nasdaq, National Research Council of Canada, Salim Dhanji https://pharmadevicenews.com/wp-content/uploads/2026/10/ME-Therapeutics-Extends-CD22-Option-e1791739834401.webp https://pharmadevicenews.com/can-accendra-health-regain-nyse-compliance-before-its-april-2027-deadline/ PharmaDeviceNews en 2026-10-11T17:27:09+00:00 Can Accendra Health regain NYSE compliance before its April 2027 deadline? Accendra Health, Apria, Byram Healthcare, Edward Pesicka, Kenneth Gardner-Smith, New York Stock Exchange, Owens & Minor, Scott Lloyd https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/vertex-alyftrek-data-show-pancreatic-function-recovery-in-young-children-with-cystic-fibrosis/ PharmaDeviceNews en 2026-10-11T16:32:40+00:00 Vertex ALYFTREK data show pancreatic function recovery in young children with cystic fibrosis ALYFTREK, Journal of Cystic Fibrosis, NACFC 2026, North American Cystic Fibrosis Conference, TRIKAFTA, United States Food and Drug Administration, Vertex Pharmaceuticals Incorporated https://pharmadevicenews.com/wp-content/uploads/2026/10/ALYFTREK-Pancreatic-Function-Gains-e1791736300853.webp https://pharmadevicenews.com/can-seaports-glyphago-overcome-agomelatines-liver-problem-new-phase-1-data-sharpen-the-test/ PharmaDeviceNews en 2026-10-11T16:26:22+00:00 Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test Agomelatine, Daniel Bonner, European College of Neuropsychopharmacology, European Medicines Agency, Glyph platform, GlyphAgo, Munich, PureTech Health, Seaport Therapeutics, SPT-320, Therapeutic Goods Administration, Valdoxan https://pharmadevicenews.com/wp-content/uploads/2026/10/Pharmaceutical-Research-Bioavailability-Briefing-e1791735930679.webp https://pharmadevicenews.com/what-bioaffinity-technologies-4m-financing-means-for-cypath-lung-growth/ PharmaDeviceNews en 2026-10-11T16:18:02+00:00 What bioAffinity Technologies’ $4m financing means for CyPath Lung growth AvMEDICAL, bioAffinity Technologies, CyPath Lung, Nasdaq, Precision Pathology Laboratory Services, San Antonio, Texas, WallachBeth Capital https://pharmadevicenews.com/wp-content/uploads/2026/10/BioAffinitys-4-Million-Financing-Boost-e1791735418373.webp https://pharmadevicenews.com/a-sutureless-heart-valve-showed-99-7-freedom-from-deterioration-what-do-corcyms-seven-year-data-really-establish/ PharmaDeviceNews en 2026-10-11T16:13:13+00:00 A sutureless heart valve showed 99.7% freedom from deterioration. What do Corcym’s seven-year data really establish? Corcym, European Association for Cardio-Thoracic Surgery, Gyrus Capital, MANTRA, Memo 4D Curve, Michael Ibrahim, Perceval Plus, SURE-AVR, TriMemo, U.S. Food and Drug Administration, University of Virginia Health https://pharmadevicenews.com/wp-content/uploads/2026/10/Corcym-Perceval-Plus_-99.7-Durability-e1791735136736.webp https://pharmadevicenews.com/affinia-presents-aftx-201-preclinical-data-and-upbeat-trial-design-at-hfsa-2026/ PharmaDeviceNews en 2026-10-11T16:08:40+00:00 Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026 Affinia Therapeutics, AFTX-201, Alexion Pharmaceuticals, AstraZeneca, BAG3, European Medicines Agency, Forge Biologics, Health Canada, Heart Failure Society of America, Hideo Makimura, Houston Methodist Hospital, Laura Richman, Rocket Pharmaceuticals, United States Food and Drug Administration, UPBEAT https://pharmadevicenews.com/wp-content/uploads/2026/10/Affinia-Advances-Heart-Gene-Therapy-Trial-e1791734860631.webp https://pharmadevicenews.com/can-weltruza-become-medincells-next-growth-driver-after-uzedy-commercial-success/ PharmaDeviceNews en 2026-10-11T14:10:52+00:00 Can Weltruza become Medincell’s next growth driver after Uzedy commercial success? Euronext Paris, European Medicines Agency, Medincell, olanzapine, SOLARIS, SteadyTeq, Teva Pharmaceutical Industries, United States Food and Drug Administration, UZEDY, Weltruza, Zyprexa Relprevv https://pharmadevicenews.com/wp-content/uploads/2026/10/FDA-Approval-Fuels-Pharma-Growth-e1791727795473.webp https://pharmadevicenews.com/why-carrot-is-buying-greenman-insightvr-after-a-609-patient-cataract-study-revealed-a-striking-difference/ PharmaDeviceNews en 2026-10-11T14:04:52+00:00 Why Carrot is buying GreenMan InSightVR after a 609-patient cataract study revealed a striking difference American Academy of Ophthalmology, Brandon Baartman, Carrot, GreenMan Vision, InSightVR, Jeremy Barlow, Matt Larson, Michael Greenwood, New Orleans, Vance Thompson Vision, Virtual Field https://pharmadevicenews.com/wp-content/uploads/2026/10/VR-Eye-Care-Cataract-Simulation-e1791727446160.webp https://pharmadevicenews.com/can-oncomatryx-omtx305-overcome-immune-resistance-in-solid-tumors/ PharmaDeviceNews en 2026-10-11T14:00:12+00:00 Can Oncomatryx OMTX305 overcome immune resistance in solid tumors? Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, HanchorBio, InxMed, OMTX305, OMTX705, Oncomatryx, Science Advances, Spain, University of Tübingen https://pharmadevicenews.com/wp-content/uploads/2026/10/Oncomatryx-OMTX305_-T-Cells-Attack-Tumors-e1791727155597.webp https://pharmadevicenews.com/why-gsks-wet-lab-validation-gives-chai-discovery-a-stronger-pharmaceutical-industry-foothold/ PharmaDeviceNews en 2026-10-11T13:54:24+00:00 Why GSK’s wet-lab validation gives Chai Discovery a stronger pharmaceutical industry foothold argenx, Bristol Myers Squibb, Chai Discovery, Chai-2, Chai-3, Christopher Austin, Eli Lilly and Company, GSK, Joshua Meier, Novartis, Pfizer https://pharmadevicenews.com/wp-content/uploads/2026/10/GSK-Chai-Discovery-AI-Collaboration-e1791726824693.webp https://pharmadevicenews.com/fda-clears-urolutions-redesigned-urinary-catheter-but-can-openflo-improve-patient-outcomes/ PharmaDeviceNews en 2026-10-11T13:48:53+00:00 FDA clears Urolution’s redesigned urinary catheter, but can OpenFlo improve patient outcomes? Centers for Disease Control and Prevention, John D. Adams Jr., OpenFlo, United States Food and Drug Administration, Urolution Medical, Weihao Qu https://pharmadevicenews.com/wp-content/uploads/2026/10/FDA-Clearance_-OpenFlo-Catheter-Advances-e1791726497682.webp https://pharmadevicenews.com/secretome-therapeutics-advances-regenerative-heart-failure-research-with-stm-01-trial-data/ PharmaDeviceNews en 2026-10-11T13:07:49+00:00 Secretome Therapeutics advances regenerative heart failure research with STM-01 trial data Ambarish Pandey, Heart Failure Society of America, HFSA 2026, Northwestern University, Secretome Therapeutics, STM-01, University of Michigan https://pharmadevicenews.com/wp-content/uploads/2026/03/Viz.ais-HCM-data-push-shows-why-cardiac-AI-is-shifting-from-detection-to-care-coordination-e1774410600198.webp https://pharmadevicenews.com/can-stuart-therapeutics-st-100-heal-damaged-corneas-a-new-fda-filing-opens-a-critical-test/ PharmaDeviceNews en 2026-10-11T13:01:49+00:00 Can Stuart Therapeutics’ ST-100 heal damaged corneas? A new FDA filing opens a critical test Dave LeCause, Eric Donnenfeld, Eric Schlumpf, New York University, PolyCol, ST-100, Stuart Therapeutics, U.S. Food and Drug Administration, Vanderbilt University Medical Center, Vezocolmitide https://pharmadevicenews.com/wp-content/uploads/2026/07/Ophthalmology-slit-lamp-examination-e1783582655190.webp https://pharmadevicenews.com/glaukos-idose-tr-cuts-eye-pressure-beyond-cataract-surgery-alone-but-will-the-advantage-last/ PharmaDeviceNews en 2026-10-11T04:18:52+00:00 Glaukos iDose TR cuts eye pressure beyond cataract surgery alone, but will the advantage last? Centers for Medicare & Medicaid Services, Glaukos Corporation, GLK-101-04, iDose TR, Travoprost, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/04/Alcon-launches-Clareon-TruPlus-as-cataract-lens-market-shifts-toward-low-trade-off-vision-gains-e1775533576948.webp https://pharmadevicenews.com/glyphago-boosted-drug-bioavailability-6-8-fold-can-seaport-solve-agomelatines-liver-safety-challenge/ PharmaDeviceNews en 2026-10-11T04:05:20+00:00 GlyphAgo boosted drug bioavailability 6.8-fold. Can Seaport solve agomelatine’s liver safety challenge? Agomelatine, European College of Neuropsychopharmacology, Glyph, GlyphAgo, PureTech Health, Seaport Therapeutics, SPT-320, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/could-a-sensor-10-times-shorter-challenge-dexcom-and-abbott-ascensia-is-betting-on-sava/ PharmaDeviceNews en 2026-10-11T04:00:56+00:00 Could a sensor 10 times shorter challenge Dexcom and Abbott? Ascensia is betting on Sava Abbott Laboratories, Ascensia Diabetes Care, Balderton Capital, Biolinq, DexCom, European Union, JamJar Investments, Norrsken VC, Pentland Ventures, PHC Holdings Corporation, Sava Technologies, Senseonics Holdings, Simplyhealth Ventures, United Kingdom https://pharmadevicenews.com/wp-content/uploads/2026/08/Over-the-counter-glucose-sensors-are-creating-a-new-wellness-market-before-the-evidence-is-settled-e1787420849776.webp https://pharmadevicenews.com/aids-healthcare-foundation-brings-an-electric-hiv-clinic-to-las-vegas-but-can-mobile-testing-improve-access-to-treatment/ PharmaDeviceNews en 2026-10-11T03:56:05+00:00 AIDS Healthcare Foundation brings an electric HIV clinic to Las Vegas, but can mobile testing improve access to treatment? AIDS Healthcare Foundation, Centers for Disease Control and Prevention, Chevy BrightDrop, Florida, Fort Lauderdale, Las Vegas, Nevada, Southern Nevada Health District, Wellness on Wheels https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic-image.webp https://pharmadevicenews.com/why-quanta-systems-ice26-award-comes-at-a-crucial-moment-for-its-surgical-laser-business/ PharmaDeviceNews en 2026-10-11T03:53:02+00:00 Why Quanta System’s ICE26 award comes at a crucial moment for its surgical laser business Cyber Ho, El.En., European Association of Urology, Filippo Fagnani, ICE26, Olivier Traxer, Quanta Magneto Technology, Quanta System, Valencia, Vapor Tunnel, Virtual Basket https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Medical-Devices.webp https://pharmadevicenews.com/verda-healthcare-joins-forces-with-astranacare-in-two-states-but-how-much-growth-can-the-deal-deliver/ PharmaDeviceNews en 2026-10-11T03:48:20+00:00 Verda Healthcare joins forces with AstranaCare in two states, but how much growth can the deal deliver? Arizona, Astrana Health, AstranaCare Partners of Arizona, AstranaCare Partners of Texas, Centers for Medicare & Medicaid Services, Houston, Phoenix, Texas, Verda Healthcare, Verda Noble Care, Verda Noble Chronic Care https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/genentechs-vamikibart-sustains-vision-gains-at-52-weeks-but-mixed-phase-iii-results-complicate-fda-review/ PharmaDeviceNews en 2026-10-11T03:44:36+00:00 Genentech’s vamikibart sustains vision gains at 52 weeks, but mixed Phase III results complicate FDA review American Academy of Ophthalmology, Genentech, MEERKAT, Roche, SANDCAT, U.S. Food and Drug Administration, Vamikibart https://pharmadevicenews.com/wp-content/uploads/2026/10/Genentechs-vamikibart-reports-durable-vision-gains-with-fewer-repeat-injections-scaled-e1791690235564.webp https://pharmadevicenews.com/can-mercks-remigromig-compete-with-anti-vegf-treatments-after-brunello-results/ PharmaDeviceNews en 2026-10-11T03:39:18+00:00 Can Merck’s remigromig compete with anti-VEGF treatments after BRUNELLO results? American Academy of Ophthalmology, BAROLO, BRUNELLO, David Guyer, Donald D'Amico, EyeBio, Merck & Co., ranibizumab, Remigromig, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp